News
Prof Martin Dreyling discusses the safety profile of the BTK inhibitor acalabrutinib in patients with mantle cell lymphoma.
In an interview, Prof Martin Dreyling discussed the approval of first-line acalabrutinib for the treatment of adult patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback